• John Charles O'Horo, James R Cerhan, Elliot J Cahn, Philippe R Bauer, Zelalem Temesgen, Jon Ebbert, Andy Abril, Omar M Abu Saleh, Mariam Assi, Elie F Berbari, Dennis M Bierle, Wendelyn Bosch, Charles D Burger, Edison J Cano Cevallos, Casey M Clements, Eva M Carmona Porquera, Natalia E Castillo Almeida, Douglas W Challener, Supavit Chesdachai, Isin Y Comba, Cristina G Corsini Campioli, Sarah J Crane, Ala S Dababneh, Mark J Enzler, Hind J Fadel, Ravindra Ganesh, De MoraesAlice GalloAGDivision of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN., John R Go, Joel E Gordon, Pooja R Gurram, Pramod K Guru, Erika L Halverson, Michael F Harrison, Heather A Heaton, Ryan Hurt, Mary J Kasten, Augustine S Lee, Emily R Levy, Claudia R Libertin, Jorge M Mallea, William F Marshall, Gautam Matcha, Anne M Meehan, Pablo Moreno Franco, William G Morice, Jennifer J O'Brien, Richard Oeckler, Steve Ommen, Caitlin P Oravec, Robert Orenstein, Natalie J Ough, Raj Palraj, Bhavesh M Patel, Vincent S Pureza, Brian Pickering, David M Phelan, Raymund R Razonable, Stacey Rizza, Priya Sampathkumar, Devang K Sanghavi, Ayan Sen, Jason L Siegel, Kai Singbartl, Aditya S Shah, Fnu Shweta, Leigh L Speicher, Gina Suh, Hussam Tabaja, Aaron Tande, Henry H Ting, Russell C Tontz, James J Vaillant, Paschalis Vergidis, Mohamed Y Warsame, Zachary A Yetmar, Catherine Cate D Zomok, Amy W Williams, and Andrew D Badley.
• Division of Infectious Diseases, Mayo Clinic, Rochester, MN; Division of Pulmonary and Critical Care Medicine, Mayo Clinic, Rochester, MN.
• Mayo Clin. Proc. 2021 Mar 1; 96 (3): 601618601-618.

ObjectiveTo report the Mayo Clinic experience with coronavirus disease 2019 (COVID-19) related to patient outcomes.MethodsWe conducted a retrospective chart review of patients with COVID-19 diagnosed between March 1, 2020, and July 31, 2020, at any of the Mayo Clinic sites. We abstracted pertinent comorbid conditions such as age, sex, body mass index, Charlson Comorbidity Index variables, and treatments received. Factors associated with hospitalization and mortality were assessed in univariate and multivariate models.ResultsA total of 7891 patients with confirmed COVID-19 infection with research authorization on file received care across the Mayo Clinic sites during the study period. Of these, 7217 patients were adults 18 years or older who were analyzed further. A total of 897 (11.4%) patients required hospitalization, and 354 (4.9%) received care in the intensive care unit (ICU). All hospitalized patients were reviewed by a COVID-19 Treatment Review Panel, and 77.5% (695 of 897) of inpatients received a COVID-19-directed therapy. Overall mortality was 1.2% (94 of 7891), with 7.1% (64 of 897) mortality in hospitalized patients and 11.3% (40 of 354) in patients requiring ICU care.ConclusionMayo Clinic outcomes of patients with COVID-19 infection in the ICU, hospital, and community compare favorably with those reported nationally. This likely reflects the impact of interprofessional multidisciplinary team evaluation, effective leveraging of clinical trials and available treatments, deployment of remote monitoring tools, and maintenance of adequate operating capacity to not require surge adjustments. These best practices can help guide other health care systems with the continuing response to the COVID-19 pandemic.Copyright © 2020 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. All rights reserved.

20 keywords...

hide…